Core Insights - The company has announced positive topline results from a Phase III open-label study of its first-in-class oral small molecule FASN inhibitor, ASC40, for moderate to severe acne patients [1] - ASC40 demonstrated good safety and tolerability, with most adverse events being mild to moderate, and no severe adverse events reported [1] - The company has also achieved all primary and key secondary endpoints in a randomized, double-blind, placebo-controlled Phase III clinical study involving 480 patients [2] Group 1 - ASC40 was evaluated in a Phase III open-label study involving 240 moderate to severe acne patients, focusing on long-term safety [1] - The primary endpoints included the incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and the rate of discontinuation due to adverse events [1] - The study showed that there were no grade 3 or 4 adverse events related to ASC40, and no deaths were reported [1] Group 2 - The mechanism of action for ASC40 involves inhibiting de novo lipogenesis (DNL) in human sebocytes, directly reducing sebum production and inflammation [2] - Excessive sebum production is a major cause of acne, and ASC40's unique mechanism sets it apart from other acne treatments that do not address the root cause [2] - The company has obtained exclusive rights for ASC40 in Greater China from Sagimet Biosciences Inc. [2]
歌礼制药-B(01672)：同类首创每日一次口服FASN抑制剂地尼法司他(ASC40)治疗痤疮的III期开放标签研究取得积极顶线结果